|Bid||0.008 x 0|
|Ask||0.010 x 0|
|Day's range||0.009 - 0.010|
|52-week range||0.006 - 0.021|
|PE ratio (TTM)||N/A|
|Earnings date||1 Mar. 2016 - 5 Mar. 2016|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.25|
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Heads of Agreement with Swisstec Health Analytics Ltd. (“Swisstec”) to work together over the next 30 days to finalise a Proposed Joint Venture (PJV) to establish a new Company, (“JV Company”). The JV Company will enable both companies to collaborate to develop a service platform using blockchain technology that will provide a marketplace for medical services and personalised health management, and will also facilitate data management and AI-based services to promote better patient outcomes.
Project Shivom to provide GTG access to a significant pool of data, particularly related to the Indian population. GTG, through access to the Indian population data to modify its risk assessment kits as well as to develop new Indian specific tests or products, including tests related to diabetes and other disease, based on opportunity and areas of need.
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce the award of an NHMRC Partnership Grant to a research team led by Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health at The University of Melbourne.